A September 27 editorial in the New York Times calls on the US Congress to pass legislation that will force pharmaceutical companies to publicly disclose all payments they make to physicians. As the editorial puts it, “Patients need to know that doctors are prescribing particular drugs for sound medical reasons — not because drug companies have bought their doctors’ loyalty.”
The editorial follows an exposé the New York Times published this past July (see the AHP report) in which it was revealed that “nearly 1/3 of the [American Psychiatric Association’s] budget comes directly from the pharmaceutical industry, in the form of journal ads, convention exhibits, and the sponsoring of fellowships, conferences, and symposia.” Continue reading NYT: Law Should Compel Disclosure of Drug Company Payments to Physicians
This item comes more from the category of history-in-the-making, rather than history proper.
The New York Times has just published an article on just how extensive the financial ties are between the pharmaceutical industry and the American Psychiatric Association (APA). According to the article, nearly 1/3 of the APA’s budget comes directly from the pharmaceutical industry, in the form of journal ads, convention exhibits, and the sponsoring of fellowships, conferences, and symposia. Continue reading Psychiatry, Pharmaceutical Funding, and Congress
Continuing in the same vein as past drug-related postings (on marijuana, antidepressants, LSD, and psychedelics), we now present a capstone bibliography on the use of psychoactive substances in the history of psychology.
A longer related resource, on the history of psychopharmacology, is forthcoming.
Continue reading Bibliography: Psychoactive drug use in psychology